148404-28-8Relevant articles and documents
Ternary fused ring substituted six-membered ring derivatives and their use in medicine
-
Paragraph 0195-0197, (2019/01/22)
The invention relates to a fused tricyclic substituted amino six-membered ring derivative and application thereof in medicine, particularly a fused tricyclic substituted amino six-membered ring derivative shown in a formula (I) or stereoisomers and pharmaceutically acceptable salts or pro-drugs of the derivative, a pharmaceutical composition comprising the derivative and use of the derivative in preparing a dipeptidyl peptidase IV (DPP-IV) inhibitor in medicine, wherein the substituents in the formula (I) are defined as in the description. The formula (I) is shown in the description.
Three-membered fused ring substituted amino six-membered ring derivative and medicine applications thereof relates to a three-membered fused ring substituted amino six-membered ring derivative as shown in the general formula
-
Page/Page column 33; 34, (2017/08/02)
The present invention relates to a three-membered fused ring substituted amino six-membered ring derivative and medicine applications thereof, and more particularly to a three-membered fused ring substituted amino six-membered ring derivative as shown in the general formula (I) or a stereoisomer of the derivative, a pharmaceutically acceptable salt, a prodrug, a medicinal composition containing the derivative and an application of the derivative to preparation of the medicine, namely a dipeptidyl peptidase IV(DPP-IV) inhibitor, wherein the definitions of the various substituents in the general formula (I) are the same as those in the specification.
Substituted heteroaryl compounds and composition thereof, and applicaitons of compounds and composition
-
, (2017/07/31)
The invention provides substituted heteroaryl compounds and a composition thereof, and applicaitons of the compounds and the composition. The compounds are compounds represented by the formula (I) or the formula (II) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the compounds represented by the formula (I) or the formula (II). The invention also provides the pharmaceutical composition comprising the compounds; the compounds and the pharmaceutical composition can adjust the activity of protein kinase, and are used for prevention, processing, treatment and remission of diseases or disorders mediated by the protein kinase.